Which has stronger earnings & valuation, AZN or GSK?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca £60.44B 3.54 £8.71B £664.00 20.79 GSK £32.78B 2.29 £2.50B £142.10 13.24

Is AZN or GSK more profitable?

GSK has a net margin of 17.78% compared to AstraZeneca's net margin of 17.19%. GSK's return on equity of 35.78% beat AstraZeneca's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.19% 22.41% 7.68% GSK 17.78% 35.78% 9.56%

Does the media refer more to AZN or GSK?

In the previous week, GSK had 7 more articles in the media than AstraZeneca. MarketBeat recorded 9 mentions for GSK and 2 mentions for AstraZeneca. GSK's average media sentiment score of 0.21 beat AstraZeneca's score of -0.22 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral GSK 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, GSK or ITH?

GSK has higher revenue and earnings than Ithaca Energy. Ithaca Energy is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK £32.78B 2.29 £2.50B £142.10 13.24 Ithaca Energy £2.95B 1.24 £230.29M -£5.10 N/A

Is GSK or ITH more profitable?

GSK has a net margin of 17.78% compared to Ithaca Energy's net margin of 7.53%. GSK's return on equity of 35.78% beat Ithaca Energy's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.78% 35.78% 9.56% Ithaca Energy 7.53% 9.33% 0.18%

Does the media favor GSK or ITH?

In the previous week, GSK had 8 more articles in the media than Ithaca Energy. MarketBeat recorded 9 mentions for GSK and 1 mentions for Ithaca Energy. Ithaca Energy's average media sentiment score of 1.32 beat GSK's score of 0.21 indicating that Ithaca Energy is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ithaca Energy 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SOPH or GSK?

GSK has a consensus target price of GBX 2,034.29, suggesting a potential upside of 8.12%. Given GSK's stronger consensus rating and higher probable upside, analysts plainly believe GSK is more favorable than Sophos Group plc (SOPH.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sophos Group plc (SOPH.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GSK 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has stronger earnings and valuation, SOPH or GSK?

GSK has higher revenue and earnings than Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L) is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sophos Group plc (SOPH.L) £726.90M 0.00 N/A £1.70 N/A GSK £32.78B 2.29 £2.50B £142.10 13.24

Do analysts recommend INDV or GSK?

GSK has a consensus target price of GBX 2,034.29, indicating a potential upside of 8.12%. Given GSK's stronger consensus rating and higher probable upside, analysts plainly believe GSK is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GSK 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has stronger earnings & valuation, INDV or GSK?

GSK has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior £1.40B 1.38 -£2.36M -£1.21 N/A GSK £32.78B 2.29 £2.50B £142.10 13.24

Is INDV or GSK more profitable?

GSK has a net margin of 17.78% compared to Indivior's net margin of 14.30%. GSK's return on equity of 35.78% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 14.30% -41.70% 2.37% GSK 17.78% 35.78% 9.56%

Does the media favor INDV or GSK?

In the previous week, GSK had 8 more articles in the media than Indivior. MarketBeat recorded 9 mentions for GSK and 1 mentions for Indivior. Indivior's average media sentiment score of 0.67 beat GSK's score of 0.21 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GSK or HCM?

GSK presently has a consensus target price of GBX 2,034.29, suggesting a potential upside of 8.12%. Given GSK's stronger consensus rating and higher probable upside, research analysts clearly believe GSK is more favorable than HUTCHMED. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, GSK or HCM?

GSK has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK £32.78B 2.29 £2.50B £142.10 13.24 HUTCHMED £548.51M 2.74 -£52.98M £53.00 3.30

Is GSK or HCM more profitable?

HUTCHMED has a net margin of 104.77% compared to GSK's net margin of 17.78%. HUTCHMED's return on equity of 41.38% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.78% 35.78% 9.56% HUTCHMED 104.77% 41.38% -5.90%

GSK (GSK) Competitors

GBX 1,881.50 -36.50 (-1.90%)

As of 05/29/2026 12:13 PM Eastern

Compare

GSK vs. AZN, ITH, SOPH, INDV, and HCM

Should you buy GSK stock or one of its competitors? MarketBeat compares GSK with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GSK include AstraZeneca (AZN), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), Indivior (INDV), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

How does GSK compare to AstraZeneca?

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

64.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 45.0% of GSK shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by insiders. Comparatively, 0.2% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£60.44B	3.54	£8.71B	£664.00	20.79
GSK	£32.78B	2.29	£2.50B	£142.10	13.24

In the previous week, GSK had 7 more articles in the media than AstraZeneca. MarketBeat recorded 9 mentions for GSK and 2 mentions for AstraZeneca. GSK's average media sentiment score of 0.21 beat AstraZeneca's score of -0.22 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.5%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. GSK pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

AstraZeneca has a beta of 0.223, meaning that its stock price is 78% less volatile than the broader market. Comparatively, GSK has a beta of 0.298, meaning that its stock price is 70% less volatile than the broader market.

AstraZeneca currently has a consensus target price of £153.33, indicating a potential upside of 11.10%. GSK has a consensus target price of GBX 2,034.29, indicating a potential upside of 8.12%. Given AstraZeneca's stronger consensus rating and higher probable upside, equities research analysts clearly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

GSK has a net margin of 17.78% compared to AstraZeneca's net margin of 17.19%. GSK's return on equity of 35.78% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.19%	22.41%	7.68%
GSK	17.78%	35.78%	9.56%

Summary

AstraZeneca and GSK tied by winning 9 of the 18 factors compared between the two stocks.

How does GSK compare to Ithaca Energy?

GSK (LON:GSK) and Ithaca Energy (LON:ITH) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, GSK had 8 more articles in the media than Ithaca Energy. MarketBeat recorded 9 mentions for GSK and 1 mentions for Ithaca Energy. Ithaca Energy's average media sentiment score of 1.32 beat GSK's score of 0.21 indicating that Ithaca Energy is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ithaca Energy	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has higher revenue and earnings than Ithaca Energy. Ithaca Energy is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£32.78B	2.29	£2.50B	£142.10	13.24
Ithaca Energy	£2.95B	1.24	£230.29M	-£5.10	N/A

GSK has a beta of 0.298, indicating that its share price is 70% less volatile than the broader market. Comparatively, Ithaca Energy has a beta of 0.353, indicating that its share price is 65% less volatile than the broader market.

GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.5%. Ithaca Energy pays an annual dividend of GBX 30.31 per share and has a dividend yield of 13.7%. GSK pays out 46.4% of its earnings in the form of a dividend. Ithaca Energy pays out -594.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Ithaca Energy is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a net margin of 17.78% compared to Ithaca Energy's net margin of 7.53%. GSK's return on equity of 35.78% beat Ithaca Energy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.78%	35.78%	9.56%
Ithaca Energy	7.53%	9.33%	0.18%

GSK currently has a consensus target price of GBX 2,034.29, suggesting a potential upside of 8.12%. Ithaca Energy has a consensus target price of GBX 205, suggesting a potential downside of 7.16%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than Ithaca Energy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Ithaca Energy	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

45.0% of GSK shares are held by institutional investors. Comparatively, 3.6% of Ithaca Energy shares are held by institutional investors. 0.2% of GSK shares are held by company insiders. Comparatively, 0.2% of Ithaca Energy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

GSK beats Ithaca Energy on 12 of the 17 factors compared between the two stocks.

How does GSK compare to Sophos Group plc (SOPH.L)?

Sophos Group plc (SOPH.L) (LON:SOPH) and GSK (LON:GSK) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Sophos Group plc (SOPH.L) pays an annual dividend of GBX 0.04 per share. GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.5%. Sophos Group plc (SOPH.L) pays out 2.4% of its earnings in the form of a dividend. GSK pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK has higher revenue and earnings than Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L) is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sophos Group plc (SOPH.L)	£726.90M	0.00	N/A	£1.70	N/A
GSK	£32.78B	2.29	£2.50B	£142.10	13.24

GSK has a net margin of 17.78% compared to Sophos Group plc (SOPH.L)'s net margin of 0.00%. GSK's return on equity of 35.78% beat Sophos Group plc (SOPH.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sophos Group plc (SOPH.L)	N/A	N/A	N/A
GSK	17.78%	35.78%	9.56%

GSK has a consensus target price of GBX 2,034.29, suggesting a potential upside of 8.12%. Given GSK's stronger consensus rating and higher probable upside, analysts plainly believe GSK is more favorable than Sophos Group plc (SOPH.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sophos Group plc (SOPH.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

45.0% of GSK shares are held by institutional investors. 0.2% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, GSK had 9 more articles in the media than Sophos Group plc (SOPH.L). MarketBeat recorded 9 mentions for GSK and 0 mentions for Sophos Group plc (SOPH.L). GSK's average media sentiment score of 0.21 beat Sophos Group plc (SOPH.L)'s score of 0.00 indicating that GSK is being referred to more favorably in the news media.

Company	Overall Sentiment
Sophos Group plc (SOPH.L)	Neutral
GSK	Neutral

Summary

GSK beats Sophos Group plc (SOPH.L) on 13 of the 15 factors compared between the two stocks.

How does GSK compare to Indivior?

Indivior (LON:INDV) and GSK (LON:GSK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.5%. Indivior pays out -1,243.7% of its earnings in the form of a dividend. GSK pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A
GSK	£32.78B	2.29	£2.50B	£142.10	13.24

In the previous week, GSK had 8 more articles in the media than Indivior. MarketBeat recorded 9 mentions for GSK and 1 mentions for Indivior. Indivior's average media sentiment score of 0.67 beat GSK's score of 0.21 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, GSK has a beta of 0.298, suggesting that its share price is 70% less volatile than the broader market.

GSK has a consensus target price of GBX 2,034.29, indicating a potential upside of 8.12%. Given GSK's stronger consensus rating and higher probable upside, analysts plainly believe GSK is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

86.0% of Indivior shares are held by institutional investors. Comparatively, 45.0% of GSK shares are held by institutional investors. 3.4% of Indivior shares are held by insiders. Comparatively, 0.2% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GSK has a net margin of 17.78% compared to Indivior's net margin of 14.30%. GSK's return on equity of 35.78% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	14.30%	-41.70%	2.37%
GSK	17.78%	35.78%	9.56%

Summary

GSK beats Indivior on 14 of the 18 factors compared between the two stocks.

How does GSK compare to HUTCHMED?

GSK (LON:GSK) and HUTCHMED (LON:HCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

GSK has a beta of 0.298, suggesting that its share price is 70% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.453, suggesting that its share price is 55% less volatile than the broader market.

45.0% of GSK shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 0.2% of GSK shares are held by insiders. Comparatively, 2.8% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HUTCHMED has a net margin of 104.77% compared to GSK's net margin of 17.78%. HUTCHMED's return on equity of 41.38% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.78%	35.78%	9.56%
HUTCHMED	104.77%	41.38%	-5.90%

GSK has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£32.78B	2.29	£2.50B	£142.10	13.24
HUTCHMED	£548.51M	2.74	-£52.98M	£53.00	3.30

In the previous week, GSK had 9 more articles in the media than HUTCHMED. MarketBeat recorded 9 mentions for GSK and 0 mentions for HUTCHMED. GSK's average media sentiment score of 0.21 beat HUTCHMED's score of 0.00 indicating that GSK is being referred to more favorably in the media.

Company	Overall Sentiment
GSK	Neutral
HUTCHMED	Neutral

GSK presently has a consensus target price of GBX 2,034.29, suggesting a potential upside of 8.12%. Given GSK's stronger consensus rating and higher probable upside, research analysts clearly believe GSK is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

GSK beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	Drug Manufacturers Industry	Medical Sector	LON Exchange
Market Cap	£75.11B	£73.53B	£6.46B	£2.80B
Dividend Yield	3.51%	2.40%	2.69%	6.07%
P/E Ratio	13.24	25.27	21.31	365.74
Price / Sales	2.29	146.63	531.24	87,758.72
Price / Cash	8.15	16.13	43.65	27.89
Price / Book	5.71	3.52	10.60	7.79
Net Income	£2.50B	£3.18B	£3.56B	£5.89B
7 Day Performance	-1.75%	0.23%	2.83%	0.82%
1 Month Performance	-2.44%	-2.73%	4.57%	10.96%
1 Year Performance	24.85%	17.72%	37.66%	78.71%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	3.3694 of 5 stars	GBX 1,881.50 -1.9%	GBX 2,034.29 +8.1%	+29.2%	£75.11B	£32.78B	13.24	70,212	Trending News Analyst Forecast High Trading Volume
AZN AstraZeneca	2.8434 of 5 stars	£137.94 +0.6%	£153.33 +11.2%	+32.7%	£213.92B	£60.44B	20.77	83,500
ITH Ithaca Energy	1.3868 of 5 stars	GBX 285.40 +0.6%	GBX 205 -28.2%	+54.2%	£4.71B	£2.95B	N/A	220
SOPH Sophos Group plc (SOPH.L)	N/A	N/A	N/A	N/A	£2.99B	£726.90M	341.41	520
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+36.3%	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GSK) was last updated on 5/30/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors